Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM): How Practice is Changing

Introduction

Diabetes mellitus represents one of the most significant global health challenges, affecting more than 537 million adults worldwide, with projections estimating an increase to approximately 783 million by 2045. The condition is associated with substantial morbidity and mortality, driven by both acute metabolic complications and long term microvascular and macrovascular sequelae, including retinopathy, nephropathy, neuropathy, and cardiovascular disease. Central to effective diabetes management is the accurate and timely monitoring of glycemic status, which guides therapeutic decision making and risk reduction strategies.

For several decades, self monitoring of blood glucose using capillary fingerstick measurements served as the standard approach to glucose assessment. While this method provided important point in time data, it was inherently limited by its episodic nature. Patients and clinicians were required to make treatment decisions based on isolated readings that did not fully capture glycemic variability, nocturnal hypoglycemia, or postprandial excursions. This fragmented view of glucose dynamics often resulted in suboptimal glycemic control and increased risk of complications.

The introduction of continuous glucose monitoring has fundamentally transformed this paradigm. Continuous glucose monitoring systems measure interstitial glucose concentrations at frequent intervals, typically every one to five minutes, generating a comprehensive and dynamic profile of glucose fluctuations over time. By providing near real time data, trend analysis, and directional arrows, these systems enable a more nuanced understanding of glycemic patterns that extends beyond static measurements. The first commercially available continuous glucose monitoring device received regulatory approval in 1999, although early iterations were limited by device size, user burden, and the need for frequent calibration with capillary glucose measurements.

Advances in sensor technology, data processing, and device integration have led to the development of modern continuous glucose monitoring systems that are more accurate, user friendly, and clinically versatile. Contemporary devices often feature factory calibration, extended sensor wear duration, and improved signal reliability. Many systems are designed to integrate seamlessly with smartphones, insulin pumps, and digital health platforms, allowing for real time data sharing between patients, caregivers, and healthcare providers. This connectivity supports remote monitoring, facilitates timely clinical interventions, and aligns with broader trends in telemedicine and patient centered care.

From a clinical perspective, continuous glucose monitoring has redefined key metrics used in diabetes management. Traditional reliance on glycated hemoglobin as the primary indicator of glycemic control is increasingly complemented by continuous glucose monitoring derived metrics such as time in range, time below range, and glycemic variability. These parameters provide a more detailed assessment of glucose control and have been associated with improved clinical outcomes, including reduced incidence of hypoglycemia and better overall metabolic stability. Randomized controlled trials and real world studies have demonstrated that continuous glucose monitoring use is associated with improved glycemic control in both type 1 and type 2 diabetes populations, particularly when combined with structured education and appropriate clinical support.

The integration of continuous glucose monitoring into routine clinical practice has also prompted a reevaluation of therapeutic strategies. Insulin dosing can now be adjusted based on trend data rather than isolated values, enabling more precise and individualized treatment. In addition, continuous glucose monitoring has facilitated the development of advanced diabetes technologies such as automated insulin delivery systems, which use algorithm driven feedback loops to modulate insulin administration in response to real time glucose levels. These systems represent a significant step toward closed loop or artificial pancreas solutions.

Despite these advances, several challenges remain in the widespread implementation of continuous glucose monitoring. Cost and reimbursement limitations continue to restrict access in many healthcare settings, particularly in low and middle income regions. Device related issues, including sensor accuracy during rapid glucose changes, skin irritation, and user adherence, may also impact effectiveness. Furthermore, the large volume of data generated by continuous glucose monitoring systems requires appropriate interpretation and clinical integration, necessitating additional training for both patients and healthcare providers.

This analysis examines the evolving role of continuous glucose monitoring in diabetes care delivery by evaluating its impact on clinical outcomes, exploring practical considerations for implementation, and addressing barriers to adoption. As healthcare systems increasingly move toward data driven and personalized models of care, continuous glucose monitoring is positioned as a central tool in optimizing diabetes management. Its ability to provide continuous, actionable insights into glycemic patterns represents a significant advancement in the effort to reduce complications and improve quality of life for individuals living with diabetes.

Evolution of Glucose Monitoring Technology

Historical Context

Before CGM technology, diabetes management relied entirely on intermittent glucose measurements. Patients performed fingerstick tests two to eight times daily, depending on their treatment regimen. This approach provided limited information about glucose patterns, particularly overnight trends and post-meal responses.

Healthcare providers based treatment decisions on these sparse data points, along with hemoglobin A1C values obtained every three months. The lack of real-time information made it difficult to identify hypoglycemic episodes, dawn phenomenon patterns, and the impact of specific foods or activities on glucose levels.

CGM Technology Development

First-generation CGM devices required finger-stick calibrations twice daily and had limited accuracy, especially in the hypoglycemic range. Sensors lasted only three to seven days, and data download required special equipment available only in clinical settings.

Current CGM systems have addressed many early limitations. Factory-calibrated sensors eliminate the need for routine fingerstick calibrations. Sensor wear time has extended to 10-14 days for most devices. Real-time data transmission to smartphones and other devices enables immediate access to glucose information.

Accuracy has improved substantially, with most modern CGMs meeting FDA standards for non-adjunctive use. This means patients can make treatment decisions based solely on CGM readings without confirmatory fingerstick tests in most situations.

Clinical Applications and Outcomes

Type 1 Diabetes Management

CGM technology has become standard of care for most patients with type 1 diabetes. Clinical trials consistently demonstrate improved outcomes when CGM is used consistently. The DIAMOND study showed a 0.6% reduction in A1C levels among adults using CGM compared to standard monitoring.

Real-world evidence supports these trial findings. A large registry study of over 30,000 patients with type 1 diabetes found that CGM users achieved better glycemic control across all age groups. The benefit was most pronounced in patients who used their devices consistently, defined as wearing the sensor more than 70% of the time.

Type 2 Diabetes Applications

The role of CGM in type 2 diabetes continues to evolve. Initially, insurance coverage limited CGM use to patients requiring insulin therapy. Recent evidence suggests benefits extend to non-insulin-treated patients as well.

The MOBILE study demonstrated that adults with type 2 diabetes on basal insulin achieved a 0.8% reduction in A1C when using CGM compared to standard monitoring. Participants also reported increased confidence in diabetes management and better understanding of how food choices affected their glucose levels.

For patients not using insulin, CGM appears most beneficial as an educational tool. Short-term CGM use can reveal glucose patterns that motivate behavior changes. Several studies have shown that even brief CGM exposure leads to improved dietary choices and increased physical activity.

Pediatric Considerations

Children and adolescents with diabetes face unique challenges that CGM technology helps address. Parents of young children can monitor glucose levels remotely using smartphone apps, reducing anxiety about overnight hypoglycemia.

Adolescents often struggle with diabetes management due to lifestyle factors and developmental issues. CGM provides discrete monitoring that doesn’t require interrupting activities for fingerstick tests. Studies show improved family dynamics and reduced diabetes-related conflict when families use CGM technology.

School settings benefit from CGM data that can be shared with nurses and teachers. Remote monitoring capabilities allow parents to track their child’s glucose levels during school hours and intervene when necessary.

Changes in Clinical Practice Patterns

Treatment Decision Making

CGM data provides information that fundamentally changes how providers approach diabetes management. Instead of relying on A1C values and limited fingerstick data, providers can analyze detailed glucose patterns over weeks or months.

The concept of “time in range” has become a key metric alongside traditional A1C goals. Time in range refers to the percentage of glucose readings between 70-180 mg/dL. This metric correlates well with A1C levels but provides additional information about glucose variability and hypoglycemic episodes.

Insulin dosing decisions can be based on CGM trends rather than single glucose values. Providers can identify patterns such as dawn phenomenon, post-meal spikes, or exercise-related glucose changes that were previously difficult to detect.

Remote Monitoring Capabilities

Many CGM systems allow data sharing with healthcare providers between office visits. This capability became particularly valuable during the COVID-19 pandemic when routine appointments were limited.

Remote monitoring enables proactive interventions when glucose patterns indicate problems. Providers can contact patients about concerning trends before they lead to complications or emergency department visits.

The volume of data generated by CGM systems requires new approaches to data analysis and interpretation. Some providers use automated alerts for specific glucose patterns, while others schedule regular data review sessions with certified diabetes educators.

Patient Education Requirements

CGM implementation requires updated patient education approaches. Patients must learn to interpret glucose trends, understand sensor limitations, and respond appropriately to alarms and alerts.

Traditional diabetes education focused on responding to specific glucose values. CGM education emphasizes trend analysis and pattern recognition. Patients learn when to take action based on glucose direction and rate of change rather than absolute values alone.

The psychological impact of continuous glucose data can be substantial. Some patients experience anxiety from constant glucose information, while others feel empowered by increased awareness. Healthcare providers must address these psychological aspects during CGM initiation and follow-up.

Table 1: Comparison of CGM Systems Currently Available

Feature	Dexcom G7	FreeStyle Libre 3	Medtronic MiniMed 780G	Guardian Connect
Sensor Duration	10 days	14 days	7 days	7 days
Calibration Required	No	No	2-4 times daily	2-4 times daily
Real-time Alerts	Yes	Yes	Yes	Yes
Mobile App Integration	Yes	Yes	Yes	Yes
Insurance Coverage	Broad	Broad	Limited	Limited
Age Indication	2+ years	4+ years	7+ years	14+ years
Prescription Required	Yes	Yes	Yes	Yes

Integration with Diabetes Technology

Insulin Pump Connectivity

The integration of CGM with insulin pump therapy has created automated insulin delivery systems, sometimes called “artificial pancreas” technology. These systems adjust insulin delivery based on CGM readings, reducing the burden of diabetes management for patients.

Hybrid closed-loop systems can automatically adjust basal insulin rates and provide correction boluses based on glucose trends. However, users must still announce meals and make decisions about exercise and illness management.

Clinical trials of these integrated systems show improved time in range and reduced hypoglycemia compared to traditional pump therapy. Real-world studies confirm these benefits extend to diverse patient populations, including children, adults, and older individuals.

Electronic Health Record Integration

Many CGM manufacturers now provide tools for integrating glucose data directly into electronic health records. This integration streamlines clinical workflows and ensures glucose information is available during patient encounters.

Automated glucose summaries can highlight key metrics like average glucose, time in range, and hypoglycemic episodes. These summaries help providers quickly assess diabetes control without manually reviewing weeks of glucose data.

However, EHR integration remains technically challenging for many healthcare systems. Data formats vary between manufacturers, and some providers lack the technical infrastructure to support direct data feeds.

Clinical Decision Support Tools

Pattern Recognition Software

Advanced analytics tools can identify glucose patterns that might not be apparent to human reviewers. These tools can detect subtle trends in dawn phenomenon, post-meal responses, or exercise effects that inform treatment adjustments.

Machine learning algorithms can predict hypoglycemic episodes based on CGM trends, potentially allowing preventive interventions. Early studies suggest these predictive tools may be particularly useful for patients with hypoglycemia unawareness.

Population Health Applications

CGM data enables population-level analysis of diabetes control within healthcare systems. Providers can identify patient groups with suboptimal glucose control and target interventions accordingly.

Quality improvement initiatives can use aggregate CGM data to measure the effectiveness of diabetes programs. Time in range metrics provide more sensitive measures of glycemic control than traditional A1C-based assessments.

Challenges and Limitations

Technology Barriers

Despite improvements in CGM technology, barriers to adoption remain. Sensor adhesion can be problematic for patients with active lifestyles or skin sensitivity. Some patients experience skin irritation or allergic reactions to sensor adhesives.

Accuracy limitations persist in certain situations. CGM readings may be less reliable during rapid glucose changes, in the hypoglycemic range, or when interstitial fluid dynamics are altered by factors like dehydration or medication use.

Technical failures, while uncommon, can disrupt diabetes management when patients become dependent on CGM data. Backup monitoring plans are essential, but many patients lose proficiency with fingerstick testing when using CGM consistently.

Cost and Access Issues

CGM systems remain expensive, with annual costs ranging from $2,000 to $6,000 depending on the device and insurance coverage. While coverage has expanded, many patients still face substantial out-of-pocket costs.

Insurance prior authorization requirements can delay CGM initiation, particularly for patients with type 2 diabetes. Documentation requirements vary between payers and can be burdensome for healthcare providers.

International access varies substantially, with many countries lacking coverage for CGM technology. This disparity creates challenges for patients traveling internationally or relocating to areas with limited access.

Data Management Challenges

The volume of data generated by CGM systems can overwhelm both patients and providers. A single patient generates over 400 glucose readings daily, along with trend information and alerts.

Standardized approaches to data interpretation remain limited. Different providers may focus on different metrics or reach different conclusions from the same glucose data. Professional organizations are working to establish best practices for CGM data analysis.

Alert fatigue represents a growing concern as patients receive multiple notifications daily from CGM systems. Customizing alert parameters to individual patient needs requires ongoing attention and adjustment.

Provider Education and Training

Clinical Competency Requirements

Effective CGM implementation requires providers to develop new clinical skills. Understanding CGM accuracy limitations, appropriate alert settings, and data interpretation methods takes time and experience.

Many medical schools and residency programs have not yet integrated CGM education into their curricula. Continuing education programs help practicing providers develop these competencies, but access to quality training varies.

Professional organizations have begun developing CGM competency standards and certification programs. These initiatives aim to ensure consistent quality in CGM implementation and follow-up care.

Team-Based Care Models

CGM implementation often works best within team-based care models that include certified diabetes educators, pharmacists, and other specialists. These team members can provide focused CGM education and ongoing support.

Certified diabetes care and education specialists often serve as CGM champions within healthcare organizations. They provide initial device training, troubleshoot technical problems, and help patients interpret glucose data.

The role of endocrinologists continues to evolve as primary care providers become more comfortable with CGM technology. Specialist referrals may focus more on complex cases or technology optimization rather than routine CGM initiation.

Patient Perspectives and Adaptation

Quality of Life Impacts

Studies consistently show improved quality of life among CGM users. Patients report increased confidence in diabetes management, reduced worry about hypoglycemia, and greater flexibility in daily activities.

Sleep quality often improves when patients use CGM with overnight low glucose alerts. Parents of children with diabetes report reduced anxiety and better sleep when using remote monitoring capabilities.

However, some patients experience information overload or anxiety from continuous glucose data. Support groups and peer mentoring programs can help patients adapt to CGM technology and develop healthy relationships with their glucose data.

Behavioral Change Facilitation

CGM provides immediate feedback on the glucose effects of food choices, physical activity, stress, and sleep patterns. This real-time information can motivate behavior changes that traditional monitoring methods cannot achieve.

Gamification features in some CGM apps encourage patients to achieve time in range goals or maintain sensor wear compliance. These features appear particularly effective for younger patients and those new to diabetes management.

The social aspects of CGM data sharing can also motivate positive behaviors. Patients who share data with family members or healthcare providers often demonstrate better glucose control than those who use CGM in isolation.

Regulatory and Reimbursement Evolution

FDA Approval Pathways

The FDA has streamlined approval pathways for CGM devices, recognizing their importance in diabetes management. New de novo pathways allow innovative features to reach patients more quickly than traditional approval processes.

Interoperability standards are being developed to ensure CGM devices can communicate effectively with other diabetes technologies. These standards will facilitate innovation while maintaining patient safety.

Insurance Coverage Trends

Medicare coverage for CGM expanded dramatically in 2017 and continues to evolve. Most major commercial insurers now cover CGM for patients with type 1 diabetes and insulin-treated type 2 diabetes.

Coverage for non-insulin-treated type 2 diabetes remains inconsistent but is gradually expanding. Some insurers cover short-term CGM use for educational purposes, while others require specific clinical criteria.

Value-based care contracts increasingly include CGM access as a covered benefit. These arrangements recognize that upfront CGM costs may reduce long-term complications and healthcare utilization.

Future Directions and Innovations

Technological Advances

Next-generation CGM systems promise longer sensor life, improved accuracy, and additional features like ketone monitoring. Some manufacturers are developing sensors that can monitor multiple metabolites simultaneously.

Non-invasive glucose monitoring remains an active area of research. While technical challenges have prevented commercial success, several promising approaches are in development.

Integration with Digital Health

CGM data increasingly integrates with digital health platforms that include nutrition tracking, physical activity monitoring, and medication adherence tools. These integrated approaches provide holistic views of factors affecting glucose control.

Artificial intelligence applications for CGM data analysis continue to evolve. These tools may eventually provide automated treatment recommendations or predict glucose trends hours in advance.

Precision Medicine Applications

CGM data combined with genetic information, continuous activity monitoring, and dietary tracking may enable personalized diabetes management approaches. These precision medicine applications could optimize treatment for individual patient characteristics.

A Brief Humorous Interlude

Dr. Sarah Chen, an endocrinologist at a major academic center, recalls her first experience with CGM technology. During a particularly busy clinic day, her patient’s CGM alarm began sounding repeatedly from his pocket. After the third alarm, she asked him to check his glucose level. He looked at his phone, chuckled, and explained that the alarms were actually text messages from his teenage daughter asking for money. His glucose was perfectly normal, but his wallet was experiencing a severe low. This incident taught Dr. Chen the importance of helping patients customize their alert settings to avoid unnecessary anxiety and disruption.

Comparison with Traditional Monitoring Approaches

Clinical Outcomes Comparison

Multiple studies have directly compared CGM with traditional fingerstick monitoring across different patient populations. The results consistently favor CGM for most clinical outcomes, including A1C reduction, time in range improvement, and hypoglycemia prevention.

A meta-analysis of 15 randomized controlled trials found that CGM use resulted in a mean A1C reduction of 0.5% compared to traditional monitoring. The benefit was consistent across age groups but was most pronounced in patients with baseline A1C levels above 8%.

Hypoglycemia detection represents perhaps the greatest advantage of CGM over traditional monitoring. Studies using blinded CGM data reveal that patients using fingerstick monitoring miss up to 80% of hypoglycemic episodes, particularly those occurring overnight.

Cost-Effectiveness Analysis

Economic analyses of CGM technology show favorable cost-effectiveness ratios when long-term complications are considered. A 20-year model found that CGM use resulted in net cost savings due to reduced hospitalizations and fewer diabetes complications.

However, upfront costs remain a barrier for many patients and healthcare systems. The cost-effectiveness improves with longer duration of use and better clinical outcomes, emphasizing the importance of supporting patient adherence to CGM therapy.

Patient Preference Studies

Patient preference studies consistently show high satisfaction with CGM technology once patients adapt to its use. A large survey of over 5,000 CGM users found that 85% would not want to return to fingerstick-only monitoring.

Preferences vary by age group and diabetes type. Younger patients particularly value the discrete nature of CGM monitoring and smartphone integration. Older patients often appreciate the peace of mind provided by hypoglycemia alerts.

Implementation Strategies for Healthcare Organizations

Workflow Integration

Successful CGM implementation requires thoughtful integration into existing clinical workflows. Many organizations designate specific staff members as CGM specialists who handle device initiation and troubleshooting.

Appointment scheduling may need modification to accommodate CGM training sessions and follow-up visits. Some organizations use group education sessions to efficiently provide CGM training to multiple patients simultaneously.

Staff Training Programs

Healthcare organizations must invest in staff training to ensure successful CGM implementation. Training programs should cover technical aspects of different CGM systems, data interpretation skills, and patient education techniques.

Ongoing education is essential as CGM technology continues to evolve rapidly. Many organizations establish relationships with device manufacturers to provide regular training updates and technical support.

Quality Assurance

Quality assurance programs help ensure consistent CGM implementation and follow-up care. These programs may include regular audits of CGM prescribing patterns, patient outcomes assessment, and staff competency evaluations.

Patient feedback mechanisms help identify areas for improvement in CGM programs. Regular surveys and focus groups can reveal unmet needs and guide program enhancements.

Special Populations and Considerations

Elderly Patients

CGM implementation in elderly patients requires special considerations related to technology literacy, manual dexterity, and cognitive function. Simplified smartphone apps and family member involvement often facilitate successful adoption.

Hypoglycemia awareness may be impaired in older adults, making CGM alarms particularly valuable for safety. However, alert settings may need customization to account for age-related changes in hypoglycemia symptoms.

Pregnancy and Gestational Diabetes

CGM use during pregnancy provides detailed information about glucose control that benefits both maternal and fetal outcomes. Studies show improved birth outcomes when CGM is used during diabetic pregnancies.

Gestational diabetes management increasingly incorporates CGM technology, particularly for patients requiring insulin therapy. The immediate feedback helps pregnant women understand how food choices affect glucose levels.

Hospital and Acute Care Settings

CGM use in hospital settings remains investigational but shows promise for reducing hypoglycemia and improving glucose control. Technical challenges include sensor accuracy during acute illness and integration with hospital protocols.

Emergency department visits for diabetes-related complications may be reduced among CGM users due to better glucose awareness and trend recognition. However, emergency providers must understand CGM limitations and when confirmatory testing is needed.

Global Perspectives and Access

International Implementation

CGM adoption varies substantially between countries based on healthcare systems, reimbursement policies, and cultural factors. European countries generally have broader CGM access through national health services.

Low- and middle-income countries face particular challenges in CGM implementation due to cost barriers and limited technical infrastructure. Some manufacturers are developing simplified CGM systems specifically for these markets.

Health Equity Considerations

Disparities in CGM access exist based on socioeconomic status, race, ethnicity, and geographic location. Rural patients may have limited access to providers experienced with CGM technology.

Language barriers can complicate CGM education and ongoing support. Multilingual educational materials and interpreter services are essential for ensuring equitable access to CGM benefits.

Key Takeaways

• CGM technology provides real-time glucose data that enables better treatment decisions than traditional monitoring methods
• Clinical outcomes consistently favor CGM use across different patient populations and diabetes types
• Implementation requires new clinical workflows, staff training, and patient education approaches
• Cost and access barriers persist but continue to improve with expanding insurance coverage
• Integration with other diabetes technologies creates opportunities for automated insulin delivery and comprehensive digital health platforms
• Healthcare providers must develop competencies in CGM data interpretation and patient support
• Future innovations promise even greater benefits through improved accuracy, longer sensor life, and artificial intelligence applications

Frequently Asked Questions

Q: How accurate are current CGM systems compared to fingerstick blood glucose meters?

Modern CGM systems have accuracy rates comparable to traditional blood glucose meters, with most meeting FDA standards for non-adjunctive use. The mean absolute relative difference (MARD) for current CGM systems ranges from 8-15%, which is similar to or better than many fingerstick meters. However, accuracy may be reduced during rapid glucose changes or in the hypoglycemic range.

Q: Can patients with type 2 diabetes who don’t use insulin benefit from CGM?

Yes, studies show that CGM can benefit non-insulin-treated patients with type 2 diabetes, particularly as an educational tool. Short-term CGM use helps patients understand how food choices, physical activity, and other factors affect their glucose levels. This information often leads to improved dietary choices and lifestyle modifications that enhance glucose control.

Q: How do healthcare providers manage the large volume of data generated by CGM systems?

Many providers use automated summary reports that highlight key metrics like average glucose, time in range, and patterns of hypoglycemia. Some healthcare systems integrate CGM data directly into electronic health records with automated alerts for concerning patterns. Team-based care models often designate certified diabetes educators to review CGM data and provide ongoing support.

Q: What are the main barriers to CGM adoption in clinical practice?

The primary barriers include cost and insurance coverage limitations, the need for provider training on new technology, patient education requirements, and data management challenges. Technical issues like sensor adhesion problems and occasional accuracy limitations also affect adoption. However, these barriers continue to diminish as technology improves and coverage expands.

Q: How do CGM systems perform during exercise and other activities?

Most modern CGM systems are designed to be waterproof and durable enough for normal physical activities including swimming and exercise. However, rapid changes in glucose during intense exercise may temporarily affect accuracy. Patients should be educated about these limitations and when confirmatory fingerstick testing might be appropriate.

Q: Are there any safety concerns with long-term CGM use?

Long-term CGM use appears to be safe for most patients. The most common issues are skin irritation or allergic reactions to sensor adhesives, which affect a small percentage of users. These problems can often be managed with barrier films or alternative adhesives. There are no known long-term health risks from the sensors themselves.

Q: How do CGM systems integrate with insulin pumps and other diabetes devices?

Many CGM systems can communicate directly with insulin pumps to create automated insulin delivery systems. These integrated systems can automatically adjust insulin delivery based on glucose readings and trends. However, patients still need to announce meals and make decisions about exercise and sick day management. Integration with smartphone apps also allows connection to other health tracking tools and electronic health records.

References

American Diabetes Association. (2023). Standards of medical care in diabetes—2023. Diabetes Care, 46(Supplement 1), S1-S291.

Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., … & DIAMOND Study Group. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA, 317(4), 371-378.

Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., … & Wolpert, H. (2018). Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care, 41(11), 2275-2280.

Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., … & iDCL Trial Research Group. (2019). Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. New England Journal of Medicine, 381(15), 1707-1717.

Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., … & Phillip, M. (2017). International consensus on use of continuous glucose monitoring. Diabetes Care, 40(12), 1631-1640.

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., … & American Diabetes Association. (2023). Diabetes technology: Standards of care in diabetes—2023. Diabetes Care, 46(Supplement 1), S111-S127.

Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., … & T1D Exchange Clinic Network. (2019). State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics, 21(2), 66-72.

Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hoss, U. (2018). Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): A multicentre, randomised controlled trial. The Lancet, 391(10128), 1367-1377.

Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., … & Wijkman, M. (2017). Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. JAMA, 317(4), 379-387.

Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., … & MOBILE Study Group. (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: A randomized clinical trial. JAMA, 325(22), 2262-2272.

Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., … & T1D Exchange Clinic Network. (2013). Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D Exchange clinic registry participants. Diabetes Care, 36(7), 2009-2014.

Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011). Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data. BMJ, 343, d3805.

Riddlesworth, T., Price, D., Cohen, N., & Beck, R. W. (2017). Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Therapeutics, 8(4), 947-951.

Rodbard, D. (2017). Continuous glucose monitoring: A review of recent studies demonstrating improved glycemic outcomes. Diabetes Technology & Therapeutics, 19(S3), S25-S37.

Tamborlane, W. V., Beck, R. W., Bode, B. W., Buckingham, B., Chase, H. P., Clemons, R., … & Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (2008). Continuous glucose monitoring and intensive treatment of type 1 diabetes. New England Journal of Medicine, 359(14), 1464-1476.

Welsh, J. B., Gao, P., Derdzinski, M., Puhr, S., Johnson, T. K., Walker, T., & Griffith, C. (2019). Accuracy, utilization, and effectiveness comparisons of different continuous glucose monitoring systems. Diabetes Technology & Therapeutics, 21(3), 128-132.